These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10383561)

  • 1. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
    Brown N; May JA; Wilcox RG; Allan LM; Wilson AM; Kiff PS; Heptinstall S
    Br J Clin Pharmacol; 1999 Jul; 48(1):57-62. PubMed ID: 10383561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans.
    de la Cruz JP; Guerrero A; González-Correa JA; Márquez E; Nacle I; Sánchez de la Cuesta F
    Eur J Clin Pharmacol; 2002 Jan; 57(11):775-80. PubMed ID: 11871383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of enteric-coated, low-dose aspirin on parameters of platelet function.
    Van Hecken A; Juliano ML; Depré M; De Lepeleire I; Arnout J; Dynder A; Wildonger L; Petty KJ; Gottesdiener K; De Hoon JN
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1683-8. PubMed ID: 12197849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).
    Elshafei MN; Imam Y; Mohamed MFH; AlSaud AE; Ahmed MS; Obeidat K; Saeid R; Ali M; Abdallah IM; Parray AS; Danjuma MI
    Medicine (Baltimore); 2020 May; 99(20):e20307. PubMed ID: 32443379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
    Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
    J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative antiplatelet effect of low-dose enteric coated aspirin.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Deykin D
    Br J Haematol; 1985 Aug; 60(4):635-42. PubMed ID: 3927970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
    Bhatt DL; Grosser T; Dong JF; Logan D; Jeske W; Angiolillo DJ; Frelinger AL; Lei L; Liang J; Moore JE; Cryer B; Marathi U
    J Am Coll Cardiol; 2017 Feb; 69(6):603-612. PubMed ID: 28089180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
    J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man.
    Böger RH; Bode-Böger SM; Gutzki FM; Tsikas D; Weskott HP; Frölich JC
    Clin Sci (Lond); 1993 May; 84(5):517-24. PubMed ID: 8504628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ; Mayo G; Price P; FitzGerald GA
    N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
    Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
    Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus.
    Gurbel PA; Bliden KP; Chaudhary R; Patrick J; Liu F; Chen G; McLeod C; Tantry US
    Am J Cardiol; 2016 Dec; 118(12):1941-1947. PubMed ID: 27769511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
    Zeymer U; Hohlfeld T; Vom Dahl J; Erbel R; Münzel T; Zahn R; Roitenberg A; Breitenstein S; Pap ÁF; Trenk D
    Thromb Haemost; 2017 Feb; 117(3):625-635. PubMed ID: 28102427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function.
    Cornelissen J; Kirtland S; Lim E; Goddard M; Bellm S; Sheridan K; Large S; Vuylsteke A
    Thromb Haemost; 2006 Mar; 95(3):476-82. PubMed ID: 16525576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2.
    Oldenhof J; Hochberg M; Schiff M; Brune K
    Curr Med Res Opin; 2010 Jun; 26(6):1497-504. PubMed ID: 20429831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin.
    Scavone M; Rizzo J; Femia EA; Podda GM; Bossi E; Caberlon S; Paroni R; Cattaneo M
    Thromb Haemost; 2020 Oct; 120(10):1442-1453. PubMed ID: 32717754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.